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1040Objective: The study objective was to review our initial experience with newly developed off-pump pulmonary
valve implantation techniques and compare outcomes with the conventional approach.
Methods: Thirteen symptomatic patients with severe pulmonary regurgitation underwent pulmonary valve
implantation, 6 without cardiopulmonary bypass (group 1: age, 28  21 years; range, 12-62; body surface
area range, 1.38-2.39 m2) and 7 with cardiopulmonary bypass (group 2: age, 23  13 years; range, 10-46;
body surface area range, 1.31-1.89 m2). Ten patients had previous repair of tetralogy of Fallot, and 3 patients
had pulmonary valvotomy/valvuloplasty.
Results:Mean operation times were 166 minutes (range, 110-240) in group 1 and 299 minutes (range, 221-375)
in group 2 (P<.001). Hemoglobin level after chest closure was 13.4 and 9.8 g/dL in groups 1 and 2, respectively
(P<.001). Postoperative chest drainage (median) was 78 and 300 mL in groups 1 and 2, respectively (P¼ .003).
Blood product requirement was zero and 3 units (median) in groups 1 and 2, respectively (P<.014). There was
no significant difference in postoperative ventilation time or lengths of intensive care unit and hospital stays
between the 2 groups. Mean follow-up was 15 months; all patients are in NewYork Heart Association I/II. Echo-
cardiography showed that peak velocity across the pulmonary valve was 2.2 and 2.0 in groups 1 and 2, respec-
tively (P ¼ .46). No patient had a paravalvular leak or more than mild pulmonary regurgitation.
Conclusions: Off-pump pulmonary valve implantation is a good alternative for pulmonary valve replacement.
The procedure reduces operating time, blood loss, and blood product requirement. (J Thorac Cardiovasc Surg
2013;145:1040-5)One of the most common late complications after repair of
congenital heart defects, such as tetralogy of Fallot, is pul-
monary regurgitation (PR). Significant PR results in pro-
gressive dilatation and dysfunction of the right ventricle,
decrease in exercise tolerance, arrhythmias, heart failure,
and increased risk of sudden death. The conventional ap-
proach of dealing with this problem is to perform pulmonary
valve replacement using cardiopulmonary bypass (CPB).
However, this approach is associated not only with long op-
erative time but also side effects related to the use of CPB.
Furthermore, because of the natural history of prosthetic
valve failure, patients often require multiple repeat open op-
erations for valve replacement over their lifetime, the reop-
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The Journal of Thoracic and Cardiovascular SurMinimally invasive pulmonary valve implantation is
therefore warranted. In recent years, percutaneous pulmo-
nary valve implantation has been developed. However,
with the percutaneous technique, a limited size of prosthesis
can be inserted, currently up to 26mm diameter with the Sa-
pien transcatheter heart valve (Edwards Lifesciences LLC,
Irvine, Calif) and up to 22 mmwith theMelody valve (Med-
tronic Inc, Minneapolis, Minn).1,2 Moreover, the technique
does not offer the opportunity of treating additional defects
that are frequently associated with severe PR, such as
pulmonary artery (PA) dilatation, and it cannot be used in
a native right ventricular outlet tract (RVOT) because it
requires a conduit for adequate fixation.
A newly developed tissue valve mounted on a self-
expanding stent, the No-React Injectable BioPulmonic
(BioIntegral Surgical Inc, Toronto, Canada) (Figure 1),
allows the pulmonary valve to be implanted without using
CPB, thereby avoiding its adverse side effects.3-5 This off-
pump pulmonary valve implantation (OPPI) technique
requires only minimal mobilization of the heart and great
vessels and thus reduces both the operative time and the
risks associated with extensive dissection, such as bleeding
and injury to the heart, great vessels, and adjacent structures
(eg, phrenic nerves). The Injectable BioPulmonic prosthesis
currently is available in sizes up to a diameter of 31 mm.gery c April 2013
Abbreviations and Acronyms
CPB ¼ cardiopulmonary bypass
ICU ¼ intensive care unit
MRI ¼ magnetic resonance imaging
OPPI ¼ off-pump pulmonary valve implantation
PA ¼ pulmonary artery
PR ¼ pulmonary regurgitation
RV ¼ right ventricular
RVOT ¼ right ventricular outlet tract
Chen et al Congenital Heart DiseaseThe valve was evolved from a previous Shelhigh injectable
pulmonic valve (Shelhigh Inc, Union, NJ) and is now CE
marked under the management of BioIntegral Surgical Inc.
We reviewed our initial experience with this valve and
compared outcomes with the conventional surgical ap-
proach to test the hypothesis that because of its reduced in-
vasiveness, implantation of the No-React Injectable valve is
associated with shorter operating time, reduced blood prod-
uct use, shorter intubation times, and decreased intensive
care unit (ICU) and hospital stays.C
H
DPATIENTS AND METHODS
This study was approved by the local ethics committee for a new inter-
ventional procedure introduced to theTrust.All patients gave their informed
consent. This is a retrospective, descriptive study of our initial experience.
Between May 2010 and January 2011, all patients requiring pulmonary
valve replacement for significant PR who had a native RVoutflow tract (ie,
had not undergone previous RV-PA conduit placement) and did not have
significant RVOT stenosis were considered for the injectable pulmonary
valve. Other anatomic factors did not influence the inclusion of patients
into either group. Indications for surgery were an aggregate assessment
of multiple factors: clinical symptoms (particularly exercise limitation as-
sessed by formal exercise testing), occurrence of arrhythmias, indexed
right ventricular (RV) end-diastolic and end-systolic volumes, RVejection
fraction, and pulmonary regurgitation pressure half-time.
Six patients underwent pulmonary valve implantation without CPB
(group 1: age, 28  21 years; range, 12-62, body surface area range,
1.38-2.39 m2), and 7 patients underwent pulmonary valve implantation
with CPB (group 2: age, 24  14 years; range, 12-46; body surface area
range, 1.31-1.89 m2). Ten patients had previously undergone repair of tetral-
ogyofFallot, and3patients had previouslyundergonepulmonaryvalvotomy.
Preoperative patient characteristics are listed in Table 1. Because of the the-
oretic benefits of avoiding CPB in high-risk cases (particularly patients with
significant comorbidities), more of these patients were included in group 1.
In group 1, the self-expanding pulmonary valve was implanted using
a transventricular approach via full sternotomy and the valve was fixed
with external sutures. In group 2, stented bioprostheses (n ¼ 5) or homo-
grafts (n ¼ 2) were implanted using CPB.
The No-React Injectable BioPulmonic valve consists of a porcine pul-
monic valve mounted inside a self-expanding Nitinol stent covered by
No-React–treated porcine pericardium (NR No-React, BioIntegral Surgi-
cal Inc). No-React is a proprietary process for detoxification of
glutaraldehyde-treated tissue.
Surgical Procedure
Under general anesthesia, the patient underwent a full median sternot-
omy. Dissection of adhesions was carried out to expose the anterior surfaceThe Journal of Thoracic and Carof the right ventricle and right atrium, main PA and its bifurcation, ascend-
ing aorta, and superior and inferior venae cavae. A cell-saver was used rou-
tinely in patients undergoing a redo procedure.
In group 1, if the main PAwas more than 29 mm in diameter, it was pli-
cated with pledgeted sutures. The PAwas then carefully sized using trans-
esophageal and epicardial echocardiography or, if plication had not been
necessary, a detailed preoperative magnetic resonance imaging (MRI)
scan. A valve 2 mm in diameter larger than the maximum size measured
was selected. The selected valvewas gently compressed into the introducer,
which is similar to a giant syringe, and slid into the provided trocar. Double
pledgeted purse-strings were then placed on the anterior surface of the
proximal RVOT just proximal to the infundibulum/infundibular patch,
avoiding calcified tissue. The location is chosen to lie immediately in
line with the PA and far enough away from the annulus of the valve to per-
mit comfortable angulation of the trocar up to the PA.
After heparinization (100 IU per kg of body weight to achieve an active
clotting time of 200-300 seconds), a stab incision was made at the site of
purse-string sutures. The injector was then slid into the RVOT and
advanced to the main PA. With the tip of the injector stabilized and the
operator’s fingers holding the PA below its bifurcation, the valve was de-
ployed in the main PA immediately distal to the native annulus. The trocar
delivery system was then withdrawn and the purse-string sutures con-
trolled. Transesophageal and epicardial echocardiogram was used to assess
the valve position throughout the process of deployment. At this stage, ma-
nipulation of the valve is still possible by the operator placing his/her finger
through the stab incision and passing it through the center of the valve.
By catching the distal end of the stent, the valve can be eased more prox-
imally, or if necessary more distally by pressing on the proximal edge of the
stent. Care must be taken not to tear the vessel because the stent has small
hooks at its proximal and distal margins to aid anchoring. The valve was
then secured with external Prolene sutures placed in the proximal and distal
rim of the valve.
In group 2, the homograft or xenograft was implanted using CPB with
standard aortic and bicaval cannulation andmild hypothermia (35C). Sim-
ilar postoperative care was provided to the 2 groups in a routine fashion,
and patients were prescribed warfarin or aspirin for 3 months.
The operative time (skin to skin), perioperative blood loss, blood prod-
ucts use (defined as any blood component, eg, packed red cells, platelets,
and fresh-frozen plasma), hemoglobin levels, chest drainage, mechanical
ventilation time, and ICU and hospital stays were recorded. Follow-up
was by clinical assessment and echocardiography in the outpatient clinic.
Statistics
Two-sample Student t tests were used to compare the means of the 2
groups. Where variables were not normally distributed, groups were com-
pared using the Mann–Whitney U test and medians (ranges) were used for
data summary. The Fisher exact test was used to compare proportions. All
tests were 2-tailed, and a 5% level of significance was used throughout.RESULTS
There were no operative deaths. During the period of
OPPI valve deployment, there was significant reduction in
cardiac output, which was always self-limiting after intro-
ducer removal. All patients were hemodynamically stable
during the postoperative period. In particular, we have expe-
rienced no episodes of coronary artery compromise during
or after deployment of the valve.
In group 1, the pulmonary valve sizes implanted were 25
mm in 3 patients, 27 mm in 1 patient, and 29 mm in 2 pa-
tients. In group 2, the pulmonary valve sizes were 21 mm
in 1 patient, 23 mm in 3 patients, 24 mm in 1 patient, anddiovascular Surgery c Volume 145, Number 4 1041
FIGURE 1. The No-React Injectable BioPulmonic (BioIntegral Surgical
Inc, Toronto, Canada) self-expanding tissue valve.
TABLE 2. Intraoperative and postoperative data
Parameters Group 1 (n ¼ 6) Group 2 (n ¼ 7)
P
value
Size of valve
(mm)
27  2 (25-29) 23  1 (21-25) .005
OT (skin to
skin, min)
166  43 (110-240) 299  57 (221-375) <.001
CPB time (min) — 109  48
Valve
deployment
time (min)
14  3 (11-20) —
Preoperative
hemoglobin
(g/dL)
14.6  0.8 (13.9-15.7) 13.5  2.0 (10.2-15.5) .25
Postoperative
hemoglobin
(g/dL)
13.4  1.7 (11.4-15.6) 9.8  1.7 (6.7-11.7) <.001
Chest drainage
(mL)
78 (50-120) 300 (210-1150) .003
Blood products
(units)
0 (0-0) 3 (2-11) .014
Intubation
time (h)
4.8 (1.5-16) 11 (5-79) .10
ICU stay (d) 1.5 (1-4) 2 (1-4) .45
Hospital stay (d) 6 (3-11) 7 (5-9) .42
Values are presented as mean  standard deviation (range) or median (range). Data
expressed as mean standard deviation (range).OT,Operative time; CPB, cardiopul-
monary bypass; ICU, intensive care unit.
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time was significantly shorter in group 1 than in group 2
(Table 2). Hemoglobin level after chest closure was signif-
icantly lower in group 2 than in group 1. Patients in group 1
had less postoperative chest drainage, and none of them
required blood product transfusion.
In group 1, a pericardial effusion developed in 1 patient
11 days after surgery, which required surgical drainage. In
group 2, 1 patient required surgical exploration for bleeding
on the day of operation.
There was no significant difference in postoperative ven-
tilation time or length of ICU and hospital stays between the
2 groups, although there was a trend toward these being
shorter in group 1. However, it should be noted that more
patients with increased body mass index and significant co-
morbidities were specifically selected for treatment using
the injectable valve.
Mean follow-up was 15 months; all patients are in New
York Heart Association I/II. Echocardiography showed that
peak velocity across the pulmonary valve was insignificantTABLE 1. Patient characteristics
Parameters Group 1 (n ¼ 6) Group 2 (n ¼ 7)
P
value
Age (y) 28.2  21 (12-62) 23.4  13 (10-46) .63
Body surface
area (m2)
1.86  0.37 (1.38-2.39) 1.02  0.22 (1.31-1.89) .16
Diagnosis at
initial
operation
Tetralogy of
Fallot
4 6
Isolated PS 1 1
PA/IVS 1 0
Data presented as number or mean  standard deviation (range). PS, Pulmonary
stenosis; PA, pulmonary atresia; IVS, intact ventricular septum.
1042 The Journal of Thoracic and Cardiovascular Surin both groups (Table 3), and no patient had a paravalvular
leak. No patient in group 1 had any PR, but in group 2, 1
patient hadmild regurgitation and 1 patient hadmild tomod-
erate regurgitation. Valve function of the new prosthesis was
excellent (Figure 2) with no regurgitation or gradient.
Follow-up MRI of the first patient at 1 year showed marked
reduction in RV end-diastolic and end-systolic volume in-
dexes and increased RV stroke volume (134 vs 76 mL/m2,
54 vs 29 mL/m2, and 158 vs 99 mL, respectively).DISCUSSION
OPPI has been reported in both animal and clinical
settings, mainly in European countries.3-9 After training
in both wet laboratory and animal models, we have
performed the first series of clinical OPPI in the United
Kingdom. The current study is the first to compare thisTABLE 3. Follow-up echocardiogram data
Parameters Group 1 (n ¼ 6) Group 2 (n ¼ 7) P value
PR .46
None 6 5
Mild 0 1
Mild to moderate 0 1
Moderate or severe 0 0
Valve velocity (m/s) 2.2 (2-2.4) 2.0 (1-3) .46
Data presented as number or median (range). PR, Pulmonary regurgitation.
gery c April 2013
FIGURE 2. Pre- and postoperative echocardiograms demonstrate the correct positioning of the injectable valve. Valve function is excellent with no regur-
gitation or gradient (A and C, preoperatively; B and D, postoperatively).
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publications using the Shelhigh injectable pulmonic valve
were limited to case reports and small case series with
relatively short-term follow-up period. So far, no long-
term follow-up data are available to confirm the durability
of the new No-React Injectable BioPulmonic valve. How-
ever, a recent publication reported excellent long-term
results for the No-React BioConduit (BioIntegral Surgical,
Inc) used in the aortic root position.10 Ten-year follow-up
demonstrated no evidence of stenosis, dilatation, or calcifi-
cation of the implanted valve. The No-React process is used
in all BioIntegral Surgical, Inc, products. It is therefore
anticipated that the durability and biocompatibility of the
porcine tissue used in the Injectable BioPulmonic valve
would be similar to those of the BioConduit.
We have found the procedure to be reproducible, and
none of our patients required conversion to CPB for a con-
ventional procedure. There was a significant reduction in
operating time in the OPPI group; the average valve deploy-
ment time (from insertion of valve to external fixation of
valve) was 14 minutes. Further, because CPB is not re-
quired, the extent of dissection of the heart and great vessels
is significantly reduced in the OPPI group. This greatly
reduces the risk of injury to the heart, great vessels, and ad-
jacent structures. Although we have not experienced any is-
sues, proximity to the coronary arteries is always a concern.
If compression is suspected, some repositioning of the valve
within the PA is possible by the operator placing his/her
index finger via the ventriculotomy into the valve (as de-
scribed above), although the valve cannot be completely
removed from the PAwithout the use of CPB.The Journal of Thoracic and CarPatients with chronic PR typically have an enlarged main
PA trunk. Furthermore, the RVOT is often dilated, and this
is a known source of ventricular arrhythmia and dysfunc-
tion.11 OPPI allows reduction in the RVOT without using
CPB, a significant advantage over percutaneous transcath-
eter valve implantation. In our OPPI group, 50% of patients
underwent plication of the main PA trunk. We found that
plication of the main PA could be easily and safely per-
formed on the beating heart and that it reshapes what is
often a conical PA trunk to a tubular form, which allows
more secure seating of the injectable valve. Secure place-
ment of the valve within the RVOT using sutures is a major
advance with this technology. Percutaneous valve deploy-
ment techniques currently require the presence of a rigid
tube into which the valve can be placed, and stability is
maintained by the force between the new valve and the
old rigid tube. Because of this, a distensible native outflow
tract is a contraindication to the use of non-CPB valve
replacement techniques. By using the reported approach,
any size and distensibility of outflow tract can safely be
managed by plicating the RVOT and fixing the valve with
sutures. However, the authors prefer not to use this approach
when important narrowing of the RVOT is present.
Another potential benefit of this approach is that the valve
can be placed in the native, distensible PA, allowing a larger
prosthesis to be placed than can be achieved using percuta-
neous techniques. The average size implanted in the OPPI
group was 4 mm larger than the conventional group. This
might be due to the necessary ‘‘oversizing’’ of the valve
for patients undergoing OPPI. Schreiber and colleagues4
recommend oversizing the implanted valve by at least 2diovascular Surgery c Volume 145, Number 4 1043
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avoid a paraprosthetic leak. In our OPPI group, all valves
implanted were oversized by at least 2 mm above the ana-
tomic measurement made using MRI or intraoperative
echocardiogram, and none of our patients had a postopera-
tive paraprosthetic leak. The biggest size of the injectable
valve currently available is 31 mm; therefore, we recom-
mend PA reduction/plication in patients with a PA trunk
larger than 29 mm. It is encouraging that none of our pa-
tients who received an injectable valve had even mild PR
at follow-up and that the median maximum velocity across
the valve was only 2.2 m/s.
The reason that the measured size of the injectable valves
used is greater than that for the sutured valves is multifacto-
rial. (1) The injectable valve sits in the PA, and the sutured
valve lies within the pulmonary annulus. (2) The injectable
valve benefits from having a smaller supporting structure.
(3). The injectable valve is deliberately oversized to ensure
adequate pressure on the adjacent vessel wall. The practice
of oversizing conventionally implanted valves recently has
been called into question. Intuitively it would be expected
that implanting a larger valvewould be beneficial. However,
a recent study has suggested that oversizing pulmonary ho-
mograft conduits in children does not significantly decrease
the incidence of allograft failure,12 whereas another study
has suggested that it is actually detrimental.13 Whether
this is true for all valve types is uncertain, but these data em-
phasize the importance of rigorous follow-up to ascertain
the performance characteristics of all implants.
We routinely use a cell-saver intraperatively for redo car-
diac procedures to limit the need for allogeneic blood trans-
fusion. Despite this, group 2 patients required an average of
3 units of blood products during their hospital stay with
a significantly greater amount of blood loss from the chest
drain compared with those who underwent OPPI. OPPI
therefore offers a potential benefits of reducing blood prod-
uct transfusion–related complications.
There was a trend toward reduced ventilation time and
length of ICU and hospital stays in our series for the inject-
able valve group, although the differences are not statisti-
cally significant. Most of these patients were extubated
soon after the operation and fit to be discharged on the
fourth operative day. The fact that the reported mean hospi-
tal stay for this group was longer than this is a reflection of
the fact that a number of patients who underwent injectable
valve implantation were specifically chosen for this ap-
proach because of significant comorbidities. Consequently,
arranging adequate out-of-hospital support for these highly
dependent patients on occasion delayed discharge. We
initially chose high-risk patients (eg, very obese and
wheelchair-bound patients) because we considered that
CPB posed a particularly high risk to them. However, it
should be noted that these results for the OPPI group are
skewed because of higher-risk patients undergoing this1044 The Journal of Thoracic and Cardiovascular Surprocedure. Table 1 shows that more obese patients under-
went OPPI. In both groups, more obese patients had longer
hospital stays. Yet, despite this, the ventilation time and ICU
and hospital stays trended to be lower in the OPPI group.
Further, because of our patient selection, for some patients
in the OPPI group who had significant comorbidities, dis-
charge was delayed for social reasons, such as home care
requirement.
Study Limitations
The study sample size is small with a relatively short
follow-up period and is not prospectively randomized.
A large-scale, multicenter, prospective, randomized trial
is therefore planned to confirm the initial findings and ascer-
tain the durability of the injectable valve.
Once the safety and durability of the injectable valve are
established, the timing and indication for pulmonary valve
implantation could be refined. If risks associated with
OPPI are confirmed to be small, earlier intervention for
PR may be warranted to prevent ventricular dilation/dys-
function and sudden lethal arrhythmias.
CONCLUSIONS
OPPI provides a good alternative for pulmonary valve re-
placement for PR after previous cardiac surgery. OPPI re-
duces operating time, blood loss, and blood products
requirement. Further follow-up is necessary to assess its
long-term performance.
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